In this insightful interview, Dr. Conor Kearney, Head of the Molecular Immunology Laboratory at the Olivia Newton-John Cancer Research Institute (ONJCRI), delves into the future of pharma and biotech. Dr. Kearney discusses the groundbreaking potential of CRISPR gene editing technology, which his team at ONJCRI is using to repair faulty genes that cause genetic disorders. He also highlights the exciting possibilities CRISPR holds for improving immune cell function in oncology, offering a glimpse into the future of precision medicine and targeted cancer therapies.
Olivia Newton-John Cancer Research Institute